CSL Balances Buyback Momentum Against Vifor Drag and an Open CEO Seat

CSL adds 41,958 shares to its buyback, part of an AUD 1.15 billion program, as it works past a US$7.1 billion Vifor impairment.

CSL has kept its foot on the accelerator of its on-market share repurchase, picking up another 41,958 of its own shares on Thursday. That brings the running total to 372,281 since the current tranche began at the end of August, part of an authorised program worth up to AUD 1.15 billion that runs through 30 June 2027.

The steady cadence of buybacks — including 65,271 ordinary shares acquired on 16 September — reflects management's preference for returning surplus capital to shareholders while steadily shrinking the share count. It is one plank of a broader capital allocation story that also includes a final dividend of US$1.62 per share, payable on 2 October following the ex-dividend date roughly two weeks ago.

A Year Marred by Vifor, and the Plan to Move Past It

The buyback runs alongside a consolidation effort shaped by the hefty write-downs booked against CSL's Vifor subsidiary. For the fiscal year ended June 2026, a pre-tax impairment of US$7.1 billion — predominantly tied to Vifor — weighed heavily on the balance sheet, compounded by US$799 million in restructuring costs.

Group revenue slipped 1% to US$15.8 billion. Behring, the largest division, contributed US$11.4 billion, while Vifor generated US$2.4 billion and the Seqirus vaccine unit US$2.0 billion.

Interim CEO Gordon Naylor is now driving cost reductions intended to fund growth initiatives. Savings have recently outpaced the original target, prompting management to raise the bar for both the current and coming year. About half of the additional savings are earmarked for growth programs, with roughly US$1.5 billion set aside for US plasma manufacturing.

Guidance: Flat Revenue, Modest Profit Growth

Management's outlook, detailed on 18 August, points to broadly stable group revenue at constant currency for the current fiscal year, paired with a moderate increase in adjusted profit. Underlying net profit after tax (NPAT) is targeted to grow around 5%, even as top-line revenue holds near prior-year levels.

Divisionally, Behring is expected to post moderate growth, helped by immunoglobulin demand that regained momentum in the second half. Vifor, by contrast, faces a revenue decline of roughly 25%.

What Investors Are Still Waiting For

Two strategic questions remain unresolved for market participants: who takes the permanent CEO role, and what becomes of the Seqirus spin-off that had originally been contemplated for the prior fiscal year. More detailed insight into half-year figures will arrive in February 2027, while the company's ordinary general meeting is scheduled for Tuesday, 27 October, where operating direction and capital strategy are likely to take centre stage.

Market Snapshot

The stock has been trading with a firm tone. In Thursday's session it climbed 1.7% to EUR 111.48, leaving it 10% below its 52-week high. Measured from the start of the year, the shares are up 10%.